SCHEMBL17256455

SCHEMBL17256455

CCC(=O)OC(=O)C(=O)OC(=O)C(C)(CC)CC

nearest known ligand 0.31

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.31
MEN1 O00255 1/20 0.31
CYP2C19 P33261 1/20 0.31
RECQL P46063 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28285055 0.78 ALDH1A1 (0.45) ALDH1A1MEN1CYP2C19RECQLKMT2A
SCHEMBL11735656 0.77 MGAM (0.39) ALDH1A1
Ammonia Solution, Strong SCHEMBL28098443 0.75 ALDH1A1 (0.43) ALDH1A1MEN1CYP2C19RECQLKMT2A
Butane SCHEMBL17256453 0.73 ALDH1A1 (0.48) ALDH1A1MEN1CYP2C19RECQLKMT2A
SCHEMBL3444201 0.73 ALDH1A1 (0.33) ALDH1A1
SCHEMBL1260957 0.72 FFAR3 (0.36) ALDH1A1CYP2C19
SCHEMBL2475483 0.71 DGAT1 (0.44) ALDH1A1CYP2C19
SCHEMBL7059566 0.69 CYP4F2 (0.33) CYP2C19
SCHEMBL779254 0.69 ALDH1A1 (0.38) ALDH1A1CYP2C19RECQLKMT2A
SCHEMBL13785298 0.67 ALDH1A1 (0.36) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115996696-A Prevention, reduction or improvement of odor of elderly people 弗门尼舍有限公司 2023-04-21 CN claimed
CN-118317958-A Tri-fused ring derivative and preparation method and application thereof 上海济煜医药科技有限公司 2024-07-09 CN disclosed
US-20230301970-A1 CARBOXAMIDE DERIVATIVES NOVARTIS PHARMACEUTICALS UK LIMITED (GB) 2023-09-28 US disclosed
US-11672782-B2 Carboxamide derivatives NOVARTIS AG (CH) 2023-06-13 US disclosed
EP-3143018-B1 CARBOXAMIDE DERIVATIVES NOVARTIS AG (CH) 2021-03-10 EP disclosed
US-20210052554-A1 CARBOXAMIDE DERIVATIVES NOVARTIS PHARMACEUTICALS UK LIMITED (GB) 2021-02-25 US disclosed
US-20200268718-A1 CARBOXAMIDE DERIVATIVES NOVARTIS AG (CH) 2020-08-27 US disclosed
US-10195181-B2 Carboxamide derivatives NOVARTIS AG (CH) 2019-02-05 US disclosed
CN-106661012-A Carboxamide derivatives 诺华股份有限公司 2017-05-10 CN disclosed
EP-3143018-A1 CARBOXAMIDE DERIVATIVES Novartis AG (CH) 2017-03-22 EP disclosed
US-20170014388-A1 CARBOXAMIDE DERIVATIVES NOVARTIS AG (CH) 2017-01-19 US disclosed
US-9403810-B2 Carboxamide derivatives NOVARTIS AG (CH) 2016-08-02 US disclosed
US-20150329529-A1 CARBOXAMIDE DERIVATIVES NOVARTIS AG (CH) 2015-11-19 US disclosed
WO-2015175796-A1 CARBOXAMIDE DERIVATIVES NOVARTIS AG (CH) 2015-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210052554-A1 CARBOXAMIDE DERIVATIVES SIRT5, SIRT7, ADCY5 ALDH1A1 350/4885MEN1 1189/4885CYP2C19 46/4885
US-20230301970-A1 CARBOXAMIDE DERIVATIVES SIRT1, ADCY5, ASIC1 ALDH1A1 183/4885MEN1 1002/4885CYP2C19 58/4885
US-20150329529-A1 CARBOXAMIDE DERIVATIVES SIRT5, SIRT7, ADCY5 ALDH1A1 350/4885MEN1 1189/4885CYP2C19 46/4885
US-11672782-B2 Carboxamide derivatives SIRT5, SIRT7, ADCY5 ALDH1A1 350/4885MEN1 1189/4885CYP2C19 46/4885
US-20200268718-A1 CARBOXAMIDE DERIVATIVES SIRT5, SIRT7, ADCY5 ALDH1A1 350/4885MEN1 1189/4885CYP2C19 46/4885
US-20170014388-A1 CARBOXAMIDE DERIVATIVES SIRT5, SIRT7, ADCY5 ALDH1A1 350/4885MEN1 1189/4885CYP2C19 46/4885
US-10195181-B2 Carboxamide derivatives SIRT5, SIRT7, ADCY5 ALDH1A1 350/4885MEN1 1189/4885CYP2C19 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.